Chapter 1393

In leandel's concept, a million dollars to buy 10% of the share is prepared for those who have passed the first phase of clinical preparation.

Clinical phase I is a safety experiment, which is prepared to test whether the drug has strong side effects.

Through this project, it is not difficult. If you take a few milligrams of guanyintu every day, it can also pass the clinical phase I test.

Therefore, the drugs with a valuation of US $10 million after the first phase of clinical treatment need to be well-known and promising.

Just like now, if Yang Rui or his laboratory has made a certain compound and passed the phase I clinical experiment, it will naturally be worth ten million.

However, Yang Rui is empty handed now.

That is to say, he used his own name to get a valuation of tens of millions of dollars.

This is $10 million in 1986, and its value is still very high. Moreover, in 80s, the biomedicine industry has some bubbles, and it can not be compared with the Internet industry. The total number of pharmaceutical companies that can produce large sums of money is quite a few.

The $15 million valuation offered by greenstone point company has washed away leandel's cognition.

Pharmaceutical companies occasionally produce one or two idiots, just like real estate developers, who always have brains to buy a piece of rotten land. However, the probability of two idiots meeting at the same time is relatively small.

Leandel looked at the manager of greenstone corner company on the left, and then at the manager of gramsco on the right, and he couldn't help thinking about it.

"1.7 million dollars, 10 percent." Gran's sandike offered another price.

Hawthorne at greenstone corner called out $1.8 million and looked at Thorndike.

Leandel is familiar with this kind of eyes. If you shout high, I'll quit.

Leandel's attention was on Thorndike's face.

Thorndike showed a proud smile and said steadily: "1.85 million dollars, 10 percent."

He doesn't have to ask a higher price. Hawthorne of greenstone corner has to save a little for the company if he wants to quit.

Hawthorne's expression was a little distorted. He hesitated for several seconds. Before Yang Rui wanted to speak, he said: "1.5 million dollars, eight percent."

At first glance, it seems that he has reduced the number. However, because the proportion of demand is smaller, the actual valuation is higher, reaching US $18.75 million. Although the valuation is only US $250000 more than that of glensk, where sandike is located, it makes the latter more entangled.

Leandel suddenly realized that what these two companies are fighting for is actually the right to participate.

For them, 10% or 8% of the equity is just a threshold for entry. What a company really spends is only a million dollars.

Even by the standards of 1986, more than $1 million is not a huge figure for pharmaceutical companies. Whether it's marketing or research investment, it's less than a month's expenditure.

However, leandel did not get the relevant authorization of the company, which made him a little worried.

Fortunately, Yang Rui soon stopped greenstone corner and glansky from asking for a price. He waved his hand and said, "one thing you may not know is that the new drug I made is going to be put into production in China."

"Why? Is it made in China? " Thorndike sat up straight.

Hawthorne and leandel also showed concern. However, compared with gramsco, greenstone corner and carliz pharmaceutical are both small and medium-sized enterprises. They have less requirements for the source of drugs.

Gramsco can't. They are world-class multinational companies. There are some differences in the sales of drugs produced in the United States or in China.

Of course, it's not totally impossible. For example, India has been producing all kinds of drugs for European and American pharmaceutical companies for a long time, and its chemical industry was once quite prosperous.

No matter what they thought, Yang Rui said with a smile: "I have two suggestions. One is to build a joint venture factory and share the benefits of production. If you don't want to, you can also sell as an agent, but this priority is lower than that of the partners of the joint venture factory. Only if the joint venture party gives up the sales, it will be handed over to other companies. "

Several white people looked at each other again.

"Professor Yang, Gaucher's disease is a rare disease, and there are only hundreds of thousands of patients in the world. If a joint venture is established, the profit in production will be very low." Hawthorne and the white man who came with him flowed for a few seconds and asked again."No Yang Rui said: "we have new ideas on enzyme replacement method. If it can be realized, we need a larger factory to accommodate it. Therefore, the production cost and profit will be higher than that of ordinary drugs. "

"Isn't it the extract from human placenta?" The white man behind Hawthorne suddenly asked.

"No Yang Rui's simple answer. As a rare disease, Gaucher's disease has been studied in the medical field, which is one of the reasons why Yang Rui chose it. If there is no previous research for more than 20 years, you have to do your own basic research. This is not a simple work, especially the requirements of modern medicine. It must be quantitative results. It is hard to admit that it is a plan or direction to take for granted, and quantitative often means long-term experiments, which is not easy.

In the early study of Gaucher's disease, enzyme replacement method is the most natural way.

The structure of glucocerebrosidase in patients with Gaucher's disease has changed, and it can't play its due role, so it's better to supplement some normal glucocerebrosidase.

If the lack of enzyme is a common species, this program is even a preliminary solution to Gaucher's disease. Unfortunately, early medical experts who studied Gaucher's disease were not able to find an easy source of glucocerebrosidase.

In fact, most of the compounds synthesized by the human body are difficult to have a stable supply. For example, insulin needed by diabetics has been studied for many generations before it has a cheap, stable and large supply.

Since there is no ready-made supply of glucocerebrosidase, it can only be found from the human body. In the end, only the human placenta is a very reluctant source of supply. After all, it is abandoned. Although there are many troubles in the collection and use, it is something that can save lives.

However, it can be imagined that when this extraction method is used, the cost of glucocerebrosidase is extremely high, and the number of Gaucher patients who can be treated is also very small.

Yang Rui's alternative is to prepare glucocerebrosidase analogues in Chinese hamster ovary cells by DNA recombination technology. Although it can not completely cure Gaucher's disease, the biweekly regimen can greatly prolong the life span of patients and reduce pain.

For hundreds of thousands of people suffering from Gaucher's disease, and for those with Gaucher's disease who will continue to have related gene mutations in the future, this is the voice of heaven.

"Is there any other way to extract without using the extract of human placenta? Is there an experimental plan? " Glansky's people continue to ask.

Yang Rui laughs and refuses to talk about DNA recombination technology. He does not have to explain the drug development plan to several representatives of pharmaceutical companies, but his confidence and the aura of Nobel Prize are shrouded in the whole laboratory.

"In principle, we are willing to participate in the joint venture." It's still gramsco's people who speak first.

"We have to think about it." Hawthorne's voice was a little low. Greenstone corner had never thought of a joint venture before.

Leandel hesitated for a moment, only regretfully said: "we quit."

Carliz's small only sales and production departments, relying on the purchase of a variety of formulas to live, they are not multinational joint venture capabilities and ambitions.

However, Yang Rui expressed his satisfaction. From his point of view, as long as he can persuade a foreign company, it means that the plan is effective. Then he can make a plan based on it. As for how to realize it, it is the work of Secretary Hu and his office.

What Yang Rui really cares about is the technology of DNA recombination. Although the recombinant DNA will be ruined by various laboratories in the next 10 or 20 years, it is still very high-end in the time when the human genome project has not been completed or even carried out.

It is a good thing for the ion channel laboratory to be able to realize and push it into practice.

……